Cas 1314097-72-7,tert-butyl 3-oxo-4-[[2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate

1314097-72-7

Post Buying Request

Basic information

Product Name: tert-butyl 3-oxo-4-[[2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate
Synonyms: tert-butyl 3-oxo-4-[[2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate
CAS NO:1314097-72-7
Molecular Formula:
Molecular Weight: 358.361
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: tert-butyl 3-oxo-4-[[2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate(CAS DataBase Reference)
NIST Chemistry Reference: tert-butyl 3-oxo-4-[[2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate(1314097-72-7)
EPA Substance Registry System: tert-butyl 3-oxo-4-[[2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate(1314097-72-7)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1314097-72-7(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1314097-72-7 Suppliers

Recommended suppliers

1314097-72-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1314097-72-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,4,0,9 and 7 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1314097-72:
(9*1)+(8*3)+(7*1)+(6*4)+(5*0)+(4*9)+(3*7)+(2*7)+(1*2)=137
137 % 10 = 7
So 1314097-72-7 is a valid CAS Registry Number.

1314097-72-7Upstream product

1314097-72-7Downstream Products

1314097-72-7Relevant academic research and scientific papers

Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model

Yu, Maolin,Ledeboer, Mark W.,Daniels, Matthew,Malojcic, Goran,Tibbitts, Thomas T.,Coeffet-Le Gal, Marie,Pan-Zhou, Xin-Ru,Westerling-Bui, Amy,Beconi, Maria,Reilly, John F.,Mundel, Peter,Harmange, Jean-Christophe

, p. 1579 - 1585 (2019)

The nonselective Ca2+-permeable transient receptor potential (TRP) channels play important roles in diverse cellular processes, including actin remodeling and cell migration. TRP channel subfamily C, member 5 (TRPC5) helps regulate a tight balance of cytoskeletal dynamics in podocytes and is suggested to be involved in the pathogenesis of proteinuric kidney diseases, such as focal segmental glomerulosclerosis (FSGS). As such, protection of podocytes by inhibition of TRPC5 mediated Ca2+ signaling may provide a novel therapeutic approach for the treatment of proteinuric kidney diseases. Herein, we describe the identification of a novel TRPC5 inhibitor, GFB-8438, by systematic optimization of a high-throughput screening hit, pyridazinone 1. GFB-8438 protects mouse podocytes from injury induced by protamine sulfate (PS) in vitro. It is also efficacious in a hypertensive deoxycorticosterone acetate (DOCA)-salt rat model of FSGS, significantly reducing both total protein and albumin concentrations in urine.

Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

Kim, Heung Jae,Kwak, Woo Young,Min, Jong Pil,Lee, Jae Young,Yoon, Tae Hyun,Kim, Ha Dong,Shin, Chang Yell,Kim, Mi Kyung,Choi, Song Hyen,Kim, Hae Sun,Yang, Eun Kyoung,Cheong, Ye Hwang,Chae, Yu Na,Park, Kyung Jin,Jang, Ji Myun,Choi, Soo Jung,Son, Moon Ho,Kim, Soon Hoe,Yoo, Moohi,Lee, Bong Jin

scheme or table, p. 3809 - 3812 (2011/07/31)

A series of β-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)- butanoyl]-3-(t-butoxymethyl)-piperazin-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1314097-72-7